share_log
Breakings ·  Nov 1 21:49
Shares of Some Liver Disease Drugmakers Rise Between 2% and 11% ; Late-Stage Data From Novo's Weight-Loss Drug Shows Improvement in Fatty Liver Disease
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment